AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

Press/Media: Press / Media

PeriodJan 19 2015

Media coverage

2

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
    Media name/outletDaily The Pak Banker (Plus Media Solutions Private Limited Publication)
    CountryPakistan
    Date1/19/15
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
    Media name/outletDaily The Pak Banker (Plus Media Solutions Private Limited Publication)
    CountryPakistan
    Date1/19/15
    PersonsFred Poordad